Analyst Rating Update on Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals (PTLA) has an average broker rating of 1.17, which is interpreted as a Strong Buy, as rated by 3 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Ranking by Zacks Investment Research for Coach Inc is 4, which is also a Sell.

Portola Pharmaceuticals (PTLA) : 2 Wall Street analysts covering Portola Pharmaceuticals (PTLA) believe that the average level the stock could reach for the short term is $50.5. The maximum price target given is $61 and the minimum target for short term is around $40, hence the standard deviation is calculated at $14.85.

For the current week, the company shares have a recommendation consensus of Buy.


Portola Pharmaceuticals (NASDAQ:PTLA): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $27.00 and $26.74 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $27.34. The buying momentum continued till the end and the stock did not give up its gains. It closed at $27.26, notching a gain of 1.26% for the day. The total traded volume was 873,657 . The stock had closed at $26.92 on the previous day.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Companys two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors, which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available, potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *